Ibrutinib

Introduction Overview

Generic Name

ibrutinib

Brand Name

Imbruvica

Dosage Form

oral capsules, oral tablets, oral suspension

Drug Class

BTK inhibitors

Pharmacokinetics

Absorption:
Ibrutinib is administered orally and is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations typically within 1 to 2 hours after dosing. The absolute bioavailability is low, estimated at approximately 3.9%, due primarily to extensive first-pass metabolism. Food intake does not substantially affect the overall exposure, but consistent administration with respect to meals is advised for optimal therapeutic outcomes. The oral suspension formulation also provides rapid systemic availability with patients advised to use the supplied measuring device for accurate dosing.

Distribution:
Following absorption, ibrutinib exhibits extensive tissue distribution with a volume of distribution approximating 1,120 L, demonstrating extensive penetration into peripheral tissues. It is highly protein-bound (>97%) primarily to albumin, which may influence distribution and interaction potential with other plasma-bound drugs. Due to its binding and distribution characteristics, ibrutinib reaches target tissues, including lymphoid tissues, effectively achieving therapeutic concentrations.

Metabolism:
Ibrutinib is extensively metabolized in the liver predominantly via the cytochrome P450 enzyme CYP3A4, with minor contributions from CYP2D6. The principal metabolic pathway is oxidative metabolism, generating several inactive metabolites. CYP3A inhibitors can markedly increase plasma exposure to ibrutinib, whereas CYP3A inducers can decrease its concentration, necessitating careful consideration of concomitant medications. Phase II metabolism involves conjugation processes facilitating renal and fecal elimination.

Elimination:
The elimination half-life of ibrutinib is approximately 4 to 6 hours, but pharmacodynamic effects persist due to irreversible covalent binding to BTK. Excretion occurs predominantly via feces (about 80%), with the remainder eliminated in urine. Since the drug forms a permanent bond with BTK, sustained inhibition lasts beyond the presence of free drug in plasma. Dose modifications or interruptions may be warranted in hepatic impairment, as impaired metabolism can increase drug accumulation, raising risk of toxicity.

Dosage Forms

Available Dosage Forms:
- Capsules: 70 mg and 140 mg strengths
- Tablets: 140 mg, 280 mg, and 420 mg strengths
- Oral suspension: 70 mg/mL concentration in 108 mL bottles with child-resistant caps

Dosages for Adults and Adolescents:
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) and Waldenström’s Macroglobulinemia (WM): 420 mg orally once daily
- Chronic Graft Versus Host Disease (cGVHD): Patients aged 12 years and older receive 420 mg once daily

Specific Patient Populations:
- Pediatric patients aged 1 year to less than 12 years with cGVHD receive 240 mg/m2 once daily (up to a maximum of 420 mg once daily) as per adjusted body surface area dosing
- Dose adjustments may be necessary in patients with hepatic impairment due to altered metabolism
- Patients undergoing surgery may require temporary interruption of ibrutinib 3 to 7 days prior and post-procedure to minimize bleeding risk
- The oral suspension is particularly indicated for pediatric patients or adults who have difficulty swallowing capsules or tablets

Clinical Guidelines:
- Imbruvica should be taken once daily at the same time each day with a full glass of water
- Capsules and tablets should be swallowed whole without crushing, chewing, or opening
- The oral suspension should be shaken well and measured using the provided device to ensure dosing accuracy
- Patients should maintain adequate hydration during prolonged illness involving vomiting or diarrhea
- Dose modifications or treatment interruption is advised in instances of severe toxicity or hematologic abnormalities

Mechanism Of Action

Ibrutinib, marketed as Imbruvica, acts as a highly selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a key enzyme in B cell receptor (BCR) signaling pathways. By covalently binding to a cysteine residue (Cys481) in the active site of BTK, ibrutinib effectively inactivates its kinase function. This inhibition disrupts the phosphorylation events critical for B-cell activation, proliferation, and survival.

At the cellular level, BTK inhibition leads to suppression of downstream signaling cascades including phospholipase Cγ2 (PLCγ2) activation and subsequent calcium mobilization. This dampens multiple signaling pathways responsible for B-cell receptor-dependent malignant B-cell clonal expansion found in disorders such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia (WM). Interrupting these pathways promotes apoptosis and decreases cellular proliferation.

Ibrutinib’s covalent and irreversible mechanism results in prolonged BTK inhibition even after plasma drug levels decline, providing continuous therapeutic effects with once-daily dosing. This contrasts with reversible inhibitors which require more frequent administration. Compared to traditional chemotherapy, ibrutinib specifically targets a molecular driver of B-cell malignancies, leading to a favorable side effect profile and improved patient outcomes.

Clinical trial data confirm that blocking BTK with ibrutinib enhances progression-free survival and overall survival in treated patients. Research also suggests the drug modulates tumor microenvironment interactions and immune cell functions, contributing to its efficacy. Comparative studies with other BTK inhibitors highlight ibrutinib’s established efficacy though newer agents may offer alternative safety or pharmacokinetic profiles. Overall, ibrutinib exemplifies targeted molecular therapy's role in modern hematologic cancer care.

Pharmacological Actions

Irreversible inhibition of Bruton’s tyrosine kinase (BTK) enzyme
Disruption of B-cell receptor (BCR) signaling leading to reduced malignant B-cell proliferation
Induction of apoptosis in cancerous B cells by interrupting survival pathways
Suppression of downstream signaling cascades including PLCγ2 activation and calcium mobilization
Modulation of cytokine receptor pathways contributing to therapeutic effects
Prolonged inhibition of BTK due to covalent bonding, allowing once-daily oral dosing
Reduction of cancer cell interaction with the tumor microenvironment
Immunomodulatory effects influencing both malignant and normal B-cell populations
Improvement of clinical outcomes in hematologic malignancies by targeted therapy
Minimal off-target kinase inhibition resulting in favorable safety profile
Inhibition of malignant B-cell migration and adhesion
Potential restoration of normal immune surveillance mechanisms

Therapeutic Or Clinical Uses

Treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults
Management of CLL/SLL with 17p deletion in adult patients
Therapy for Waldenström’s macroglobulinemia (WM) in adults
Treatment of chronic graft versus host disease (cGVHD) in adult and pediatric patients aged 1 year and older following failure of prior systemic therapies
First-line treatment option for previously untreated CLL/SLL patients
Combination therapy with obinutuzumab or rituximab for previously untreated CLL/SLL patients
Extension of progression-free survival and overall survival in CLL/SLL as shown in clinical trials
Use in patients intolerant or refractory to conventional chemotherapy regimens
Management of B-cell malignancies driven by aberrant BTK activity
Off-label use under clinical trials for additional hematologic cancers

Side Or Adverse Effects

Diarrhea occurring in approximately 59% of patients
Bruising and petechiae, noted in over 50% of cases
Upper respiratory tract infections in nearly half of patients
Fatigue and tiredness reported by approximately one-third of patients
Musculoskeletal pains including joint pain and muscle spasms
Rash and skin infections representing about a quarter of adverse events
Fever and chills indicating potential immune reactions or infection
Respiratory symptoms including cough and sinusitis
Headache and dizziness possibly related to neurological effects
Nausea and vomiting affecting gastrointestinal tolerance
High blood pressure occurring in 16-19% with risk of severe hypertension
Low appetite and weight changes
Serious hemorrhagic events including intracranial and gastrointestinal bleeding
Cardiac arrhythmias such as atrial fibrillation, ventricular arrhythmias, and heart failure
Blood count abnormalities including neutropenia, thrombocytopenia, and anemia
Second primary malignancies including non-melanoma skin cancers
Rare tumor lysis syndrome presenting with metabolic disturbances
Potential liver and kidney function abnormalities
Serious infections including bacterial, viral (hepatitis B reactivation), fungal infections, and progressive multifocal leukoencephalopathy

Precautions

Monitor patients for signs of bleeding and discontinue therapy if serious hemorrhage occurs
Assess and monitor blood counts regularly to manage cytopenias
Evaluate cardiovascular risk factors prior to and during therapy, including blood pressure monitoring
Consider infection prophylaxis in patients at heightened risk for opportunistic infections, including Pneumocystis jirovecii pneumonia and herpes simplex virus
Exercise caution in patients with a history of bleeding disorders or who are on anticoagulant/antiplatelet agents
Regular hepatic and renal function tests are recommended during treatment
Avoid grapefruit products and Seville oranges due to CYP3A interactions affecting drug levels
Implement effective contraception for both male and female patients due to teratogenicity risk
Temporarily withhold treatment before and after surgeries depending on bleeding risk
Advise patients to stay hydrated especially during episodes of vomiting or diarrhea to prevent dehydration
Close monitoring for development of hypertension and initiation of antihypertensive therapy as needed
Be vigilant for neurological symptoms suggestive of progressive multifocal leukoencephalopathy
Educate patients about signs of infection and instruct them to report symptoms promptly
Dose adjustments may be needed for patients with moderate to severe hepatic impairment
Patient counseling on avoiding activities that increase bleeding risk such as contact sports

Warnings

Serious hemorrhage including fatal intracranial and gastrointestinal bleeding events reported
Risk of infections including serious bacterial, viral, and fungal infections with potential for life-threatening complications
Progressive multifocal leukoencephalopathy has occurred and can lead to death or severe disability
Hypertension is common, with rates increasing over treatment duration; may lead to cardiovascular complications
Cardiac arrhythmias such as atrial fibrillation, atrial flutter and sudden cardiac death have been observed
Blood count abnormalities including neutropenia and thrombocytopenia increase risk of infection and hemorrhage
Increased incidence of secondary primary malignancies, including skin cancers
Tumor lysis syndrome has been reported infrequently but requires vigilance
Potential fetal harm leading to embryofetal toxicity; contraindicated in pregnancy
Concomitant use with strong CYP3A inhibitors or inducers can cause significant alterations in drug exposure
Risk of bleeding heightened with concomitant anticoagulant or antiplatelet therapies
Use with caution in patients with pre-existing cardiac disease or risk factors
Discontinue if severe hypersensitivity or anaphylactic reactions occur
Patients should avoid activities with high bleeding risk during treatment
Monitor for liver toxicity and discontinue if serious hepatotoxicity develops

Contraindication

Known hypersensitivity to ibrutinib or any components of the formulation
Concurrent use with strong CYP3A inhibitors or inducers without appropriate dose adjustment
Patients with active serious bleeding conditions
Pregnancy due to high risk of fetal harm and malformations
Breastfeeding mothers should not use due to unknown risks to nursing infants
Patients unable to swallow capsules or tablets if oral suspension is not available and no alternative formulation is feasible
Severe hepatic impairment where dosage modification is not established
Patients with known hypersensitivity to excipients in capsules, tablets or oral suspension such as lactose or benzyl alcohol
Use contraindicated in settings where irreversible BTK inhibition poses unacceptable risk per clinical judgment

Drug Interactions

Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) greatly increase ibrutinib plasma levels and risk toxicity
Strong CYP3A inducers (carbamazepine, rifampin, phenytoin, phenobarbital) decrease ibrutinib levels reducing efficacy
Antiplatelet agents and anticoagulants increase risk of serious bleeding events
Verapamil and erythromycin, moderate CYP3A inhibitors, may elevate plasma concentrations
Grapefruit juice and Seville oranges inhibit CYP3A and increase systemic drug exposure
Glucocorticoids may induce CYP3A and reduce drug effectiveness
Concurrent use with drugs affecting P-glycoprotein may alter absorption or disposition
Other medications causing bone marrow suppression may compound hematological toxicities
CNS depressants or drugs causing dizziness may exacerbate neurological side effects
Herbal supplements like St. John's Wort induce CYP3A and reduce ibrutinib efficacy
Co-administration with certain immunosuppressants requires careful monitoring
Drug interactions may necessitate dose adjustments or avoidance of concomitant administration
Careful assessment of all prescription, OTC, and herbal products is essential before initiating therapy
Regular monitoring for signs of toxicity or reduced efficacy is warranted during co-therapy

Preparations Of The Drug

Capsules available in strengths of 70 mg and 140 mg formulated with croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and excipients including gelatin capsule shells
Tablets offered in 140 mg, 280 mg, and 420 mg strengths containing colloidal silicon dioxide, lactose monohydrate, povidone, and film coatings with iron oxides and polyvinyl alcohol
Oral suspension containing 70 mg/mL of ibrutinib, with inactive ingredients such as benzyl alcohol, citric acid monohydrate, hypromellose, microcrystalline cellulose, carboxymethylcellulose sodium, purified water, and sucralose for palatability
Packaged in bottles with child-resistant caps for capsules and oral suspension to enhance safety
Tablets designed for whole swallow without crushing or breaking to maintain drug stability and bioavailability
Oral suspension supplied in 150 mL bottles containing 108 mL of suspension, requiring shaking prior to dosing
Storage recommendations include room temperature control (20°C to 25°C) away from moisture and heat, with oral suspension refrigeration allowed after opening but not freezing
Each formulation is manufactured by Janssen Biotech, Inc. and Pharmacyclics LLC following stringent pharmaceutical quality standards
Dosage forms permit flexible therapeutic dosing across adult and pediatric populations
Excipients selected to optimize stability, absorption, and patient tolerability